India’s Eris Lifesciences on Friday launched one of the most affordable versions of Ozempic so far, with the lowest dosage of generic semaglutide starting at 1,290 rupees ($13.8) per month. Launch under the brand Sundae in India for diabetes, with lowest dose of a Sundae vial, at 2 mg. Natco Pharma, Eris’ partner for the semaglutide launch, priced its lowest 2 mg dose at 1,290 rupees a month. Eris also plans to launch a pen device version of Sundae in April, in three dosages. The lowest 2 mg dose will cost 4,000 rupees per month and the highest 8 mg dose 4,500 rupees per month. Eris is among dozens of Indian drugmakers that are launching generic semaglutide as Danish drugmaker Novo Nordisk’s semaglutide patent is set to expire on March 20. Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India Larger peer Dr Reddy’s is expected to launch on Saturday. Indian generic drugmakers, known globally for producing low-cost medicines, are expected to price their generics at discounts of at least 50% to 60%.

Eris Lifesciences has forged a strategic partnership with Natco Pharma for commercialisation of semaglutide in India.

… strategic partnership with Natco Pharma Limited for the commercialisation … Natco Pharma has received approval from the Central Drugs Standard … Bulls Keywords ErisLifesciences INE406M01024 Pharmaceuticals Partnership NatcoPharma Semaglutide IndiaLaunch

Shares of Natco Pharma and Eris Lifesciences climbed on Tuesday after announcing a partnership to commercialise Semaglutide in India. Natco rose over 6% to its highest level since January 8, while Eris gained nearly 4%, marking its third straight session of gains.

Eris Lifesciences has partnered with Natco Pharma to introduce semaglutide in the Indian market a cutting-edge therapy for Type 2 diabetes and obesity management. By combining Eris’s strong commercial network with Natco’s proven production capabilities, the alliance expands Eris’s diabetes care portfolio with a high-impact, next-generation treatment.

Natco Pharma has received regulatory approval in India, paving the way for a launch in March 2026

In this briefing: Swiggy (3QFY26 Results Review): FD Beats Expectation, QC Burn Likely Peaked. Maintain BUY Eris Lifesciences: Steady Growth Visibility; Valuation in Comfort Zone. Upgrade to BUY ICICI Prudential AMC (ICICIAMC IN): Partial Global Index Inclusion with Low Float What Does Silver's Volatility Mean for Markets? Auto Sector Update: India EU FTA Update 1. Swiggy (3QFY26 Results Review): FD Beats Expectation, QC Burn Likely Peaked. Maintain BUY Overall B2C GOV grew 49% YoY (8.6% QoQ) to reach INR 181.2bn (in-line) Consolidated adj EBITDA losses stood at INR7.1bn (in-line) Food delivery (FD) GOV grew 20.5% YoY to INR 89.6bn (HSIE: INR 88bn) Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below. 2. Eris Lifesciences: Steady Growth Visibility; Valuation in Comfort Zone. Upgrade to BUY We upgrade Eris Lifesciences (Eris) to BUY (from ADD) with a TP of INR 1,730, based on a 28x Q3FY28E EPS (vs 31x Q2FY28E; implies EV/ EBITDA of 16x and PE of 24x for ex-amortization EPS), as we believe since our downgrade to ADD in Jul-25, the stock price has corrected (down 25% in the last six months), which factors in the growth concern in key therapies Now, the valuation has turned attractive (trading at 36/ 26/ 21x on FY25/26/27E PE vs its 5-year average of ~25x) and is providing comfort We expect Eris to focus on the execution phase after its aggressive investments (multiple M&As over FY23–25 and invested INR 38–40bn) for the next few years with focus on anti-diabetic (insulins), obesity (GLP-1) categories, and new FDC launches (~20+ in FY27) Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

In this briefing: Eris Lifesciences: Steady Growth Visibility; Valuation in Comfort Zone. Upgrade to BUY ICICI Prudential AMC (ICICIAMC IN): Partial Global Index Inclusion with Low Float What Does Silver's Volatility Mean for Markets? Auto Sector Update: India EU FTA Update Union Budget 2026- What We like and What We Don't 1. Eris Lifesciences: Steady Growth Visibility; Valuation in Comfort Zone. Upgrade to BUY We upgrade Eris Lifesciences (Eris) to BUY (from ADD) with a TP of INR 1,730, based on a 28x Q3FY28E EPS (vs 31x Q2FY28E; implies EV/ EBITDA of 16x and PE of 24x for ex-amortization EPS), as we believe since our downgrade to ADD in Jul-25, the stock price has corrected (down 25% in the last six months), which factors in the growth concern in key therapies Now, the valuation has turned attractive (trading at 36/ 26/ 21x on FY25/26/27E PE vs its 5-year average of ~25x) and is providing comfort We expect Eris to focus on the execution phase after its aggressive investments (multiple M&As over FY23–25 and invested INR 38–40bn) for the next few years with focus on anti-diabetic (insulins), obesity (GLP-1) categories, and new FDC launches (~20+ in FY27) Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

• Unveils India’s First Hypertension Anthem • National Doctors’ Movement Gains Momentum to Bridge the Diagnosis-to-Control Gap Across India MUMBAI, India, Jan. 27, 2026 /PRNewswire/ — Marking the 77th Republic Day with a call for national health unity, Eris Lifesciences hosted the One India Conclave to address the growing crisis of hypertension in the country. […]